Within the melanoma microenvironment, aberrant ERK signaling—driven by oncogenic BRAF mutations—induces MITF degradation via a ubiquitin-mediated proteasomal pathway, contributing to dysregulated melanocytic lineage commitment and tumor progression (Figure 2) [1]. The gene discussed is MITF; the disease is neoplasm.